In this interview with Tony Veverka, Chief Group Executive of BioEden, Mr. Veverka discusses how dental stem cells will impact our future. BioEden is a global stem cell storage company with laboratories in the UK and USA and sales operations in 19 countries. BioEden is also the world’s first international biobank company to collect, assess, and cryogenically store living stem cells from deciduous baby teeth.
Stem Cells for ALS: Everything You Need to Know
Although records of ALS aren’t kept everywhere in the country, doctors estimate that between 12,000 and 15,000 people in the United States have it. Though this nerve disease is relatively rare, the illness has a devastating, paralyzing effect on the people who have it.
As of now, ALS isn’t curable. However, many clinical trials show promising results in treating it in the future. Among these trials, the use of stem cells for ALS stands out as an innovative solution.
In this article, we’ll cover everything you need to know about where stem cell therapy stands as a possible solution to Lou Gehrig’s disease. Let’s get started! [Read more…]
Pluristyx and Qkine Announce a Reciprocal Distribution Agreement in Support of Optimized Growth Factor Differentiation of Induced Pluripotent Stem Cell (iPSC)
SEATTLE, WA and CAMBRIDGE, UK — Pluristyx, a leading provider of clinical-grade induced pluripotent stem cell (iPSC) solutions, and Qkine, a pioneer in the manufacture of high-purity, animal-free growth factors and cytokines, today announced a distribution agreement to support streamlined and efficient R&D and manufacturing of differentiated cells and tissues from iPSC. This collaboration will provide researchers, product manufacturers, and therapeutic developers with a streamlined, high-performance workflow, pre-qualified to deliver reliable differentiation of iPSCs into product cells and tissues. [Read more…]
Cartherics and Catalent Expand Partnership, Securing Clinical-Grade iPSC Line for Next-Generation CAR-NK Therapies
MELBOURNE, Australia & TAMPA, FL – Cartherics Pty Ltd, a biotech company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, has announced an enhanced partnership.
The companies have signed an amended commercial license agreement enabling the use of a Catalent cGMP‑compliant induced pluripotent stem cells (iPSC) line for the manufacture and commercialization of Cartherics’ iPSC-derived Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapies. The agreement supports Cartherics’ mission to develop immune cell therapy products for the treatment of cancer and endometriosis. [Read more…]
South Korean-based “iPS Bio” Establishes Japanese Subsidiary, Deepening Ties to Japan’s iPSC Ecosystem
A South Korea–based regenerative medicine company, iPS Bio, Inc., is accelerating its international footprint with the establishment of a new Japanese subsidiary in Yokohama, Kanagawa Prefecture. The move reflects a broader trend of cross-border collaboration in the induced pluripotent stem cell (iPSC) sector, particularly between leading innovation hubs in East Asia. [Read more…]
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 202
- Next Page »